Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysis.

Mirian C, Duun-Henriksen AK, Juratli T, Sahm F, Spiegl-Kreinecker S, Peyre M, Biczok A, Tonn JC, Goutagny S, Bertero L, Maier AD, Møller Pedersen M, Law I, Broholm H, Cahill DP, Brastianos P, Poulsgaard L, Fugleholm K, Ziebell M, Munch T, Mathiesen T.

J Neurol Neurosurg Psychiatry. 2020 Apr;91(4):378-387. doi: 10.1136/jnnp-2019-322257. Epub 2020 Feb 10. Review.

PMID:
32041819
2.

Microscopic brain invasion in meningiomas previously classified as WHO grade I is not associated with patient outcome.

Biczok A, Jungk C, Egensperger R, von Deimling A, Suchorska B, Tonn JC, Herold-Mende C, Schichor C.

J Neurooncol. 2019 Dec;145(3):469-477. doi: 10.1007/s11060-019-03312-x. Epub 2019 Nov 11.

PMID:
31713016
3.

Significance of cerebrospinal fluid inflammatory markers for diagnosing external ventricular drain-associated ventriculitis in patients with severe traumatic brain injury.

Lenski M, Biczok A, Neufischer K, Tonn JC, Briegel J, Thon N.

Neurosurg Focus. 2019 Nov 1;47(5):E15. doi: 10.3171/2019.8.FOCUS19407.

PMID:
31675710
4.

Stereotactic Internal Shunt Placement in Congenital Intracranial Cysts.

Lenski M, Biczok A, Tonn JC, Kreth FW.

World Neurosurg. 2019 Mar;123:e670-e677. doi: 10.1016/j.wneu.2018.11.250. Epub 2018 Dec 18.

PMID:
30576829
5.

Contrast enhancement is a prognostic factor in IDH1/2 mutant, but not in wild-type WHO grade II/III glioma as confirmed by machine learning.

Suchorska B, Schüller U, Biczok A, Lenski M, Albert NL, Giese A, Kreth FW, Ertl-Wagner B, Tonn JC, Ingrisch M.

Eur J Cancer. 2019 Jan;107:15-27. doi: 10.1016/j.ejca.2018.10.019. Epub 2018 Dec 7.

PMID:
30529899
6.

Role of Cerebrospinal Fluid Markers for Predicting Shunt-Dependent Hydrocephalus in Patients with Subarachnoid Hemorrhage and External Ventricular Drain Placement.

Lenski M, Biczok A, Huge V, Forbrig R, Briegel J, Tonn JC, Thon N.

World Neurosurg. 2019 Jan;121:e535-e542. doi: 10.1016/j.wneu.2018.09.159. Epub 2018 Sep 27.

PMID:
30268545
7.

18F-FET-PET as a biomarker for therapy response in non-contrast enhancing glioma following chemotherapy.

Suchorska B, Unterrainer M, Biczok A, Sosnova M, Forbrig R, Bartenstein P, Tonn JC, Albert NL, Kreth FW.

J Neurooncol. 2018 Sep;139(3):721-730. doi: 10.1007/s11060-018-2919-0. Epub 2018 Jun 8.

PMID:
29948765
8.

TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas.

Biczok A, Kraus T, Suchorska B, Terpolilli NA, Thorsteinsdottir J, Giese A, Tonn JC, Schichor C.

J Neurooncol. 2018 Sep;139(3):671-678. doi: 10.1007/s11060-018-2912-7. Epub 2018 May 28.

PMID:
29808339
9.

Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma.

Suchorska B, Giese A, Biczok A, Unterrainer M, Weller M, Drexler M, Bartenstein P, Schüller U, Tonn JC, Albert NL.

Neuro Oncol. 2018 Jan 22;20(2):279-288. doi: 10.1093/neuonc/nox153.

Supplemental Content

Loading ...
Support Center